AB50-ASA2-AA8,7,973. The department of administration shall reimburse members of the task 8force for their actual and necessary expenses incurred in carrying out their 9functions. AB50-ASA2-AA8,7,11111. The task force shall examine all of the following topics: AB50-ASA2-AA8,7,1612a. The systemic causes behind violence that African American women and 13girls experience, including patterns and underlying factors that explain why 14disproportionately high levels of violence occur against African American women 15and girls, including underlying historical, generational, social, economic, 16institutional, and cultural factors that may contribute to the violence. AB50-ASA2-AA8,7,1917b. Appropriate methods for tracking and collecting data on violence against 18African American women and girls, including data on missing and murdered 19African American women and girls. AB50-ASA2-AA8,7,2320c. Policies and institutions such as policing, child welfare, coroner practices, 21and other governmental practices that impact violence against African American 22women and girls and the investigation and prosecution of crimes of gender violence 23against African American people. AB50-ASA2-AA8,8,2
1d. Measures necessary to address and reduce violence against African 2American women and girls. AB50-ASA2-AA8,8,53e. Measures to help victims, victims’ families, and victims’ communities 4prevent and heal from violence that occurs against African American women and 5girls. AB50-ASA2-AA8,8,762. The task force shall, by December 31, 2025, and December 31, 2026, submit 7to the governor a report that includes all of the following: AB50-ASA2-AA8,8,98a. Proposed institutional policies and practices that are effective in reducing 9gender violence and increasing the safety of African American women and girls. AB50-ASA2-AA8,8,1110b. Recommendations to eliminate violence against African American women 11and girls. AB50-ASA2-AA8,8,1312c. Recommendations to help victims and communities heal from gender 13violence and violence against African American women and girls. AB50-ASA2-AA8,8,21143. In accomplishing the tasks in subds. 1. and 2., the task force shall seek out 15and enlist the cooperation and assistance of nongovernmental organizations, 16community and advocacy organizations working with the African American 17community, and academic researchers and experts, specifically those specializing in 18violence against African American women and girls, representing diverse 19communities disproportionately affected by violence against women and girls, or 20focusing on issues related to gender violence and violence against African American 21women and girls.”. AB50-ASA2-AA8,9,5
1(1) Home-delivered meals. In the schedule under s. 20.005 (3) for the 2appropriation to the department of health services under s. 20.435 (1) (dh), the 3dollar amount for fiscal year 2025-26 is increased by $10,475,600 and the dollar 4amount for fiscal year 2026-27 is increased by $11,248,800 to increase the funding 5available for home-delivered meals under s. 46.80 (5) (a).”. AB50-ASA2-AA8,9,128(1) Home and community based services. In the schedule under s. 20.005 9(3) for the appropriation to the department of health services under s. 20.435 (4) 10(bd), the dollar amount for fiscal year 2025-26 is increased by $2,596,300 and the 11dollar amount for fiscal year 2026-27 is increased by $2,608,100 to provide ongoing 12funding for all of the following: AB50-ASA2-AA8,9,1613(a) Aging and disability resource centers information technology projects 14focused on client-tracking and a searchable public-facing provider directory, as well 15as a centralized, statewide toll-free phone number and reception service to connect 16people with their local aging and disability resource center. AB50-ASA2-AA8,9,1917(b) The No Wrong Door - Supporting Kids Together Wisconsin initiative, 18through which parents with children who are disabled can access services and 19referrals from a single toll-free phone line and website. AB50-ASA2-AA8,9,2120(c) The resident and assisted living facility assessment tool, which allows for 21data collection and reporting relating to resident acuity and other factors.”. AB50-ASA2-AA8,10,8
1(1) Supplemental security income state benefit increase. In the 2schedule under s. 20.005 (3) for the appropriation to the department of health 3services under s. 20.435 (4) (ed), the dollar amount for fiscal year 2025-26 is 4increased by $714,000 and the dollar amount for fiscal year 2026-27 is increased by 5$14,933,500 to increase monthly state supplements to the federal supplemental 6security income case benefit from $83.78 to $100 per month for the standard state 7supplement, and from $179.77 per month to $214.57 for “exceptional expense” state 8supplements.”. AB50-ASA2-AA8,10,1610“Section 6. 20.005 (3) (schedule) of the statutes: at the appropriate place, 11insert the following amounts for the purposes indicated: AB50-ASA2-AA8,717Section 7. 20.437 (2) (c) of the statutes is created to read: AB50-ASA2-AA8,10,191820.437 (2) (c) Child care quality improvement program. The amounts in the 19schedule for the program under s. 49.133. AB50-ASA2-AA8,11,52149.133 Child care quality improvement program. (1) The department 22may establish a program under which it may, from the appropriation under s. 2320.437 (2) (c) and the allocation under s. 49.175 (1) (qm), make monthly payments
1and monthly per-child payments to child care providers certified under s. 48.651, 2child care centers licensed under s. 48.65, and child care programs established or 3contracted for by a school board under s. 120.13 (14). The department may 4investigate and recover from payment recipients under this section amounts 5overpaid or obtained through fraud. AB50-ASA2-AA8,11,96(2) If the department establishes the program under sub. (1), the department 7shall promulgate rules to implement the program, including establishing eligibility 8requirements and payment amounts and setting requirements for how recipients 9may use the payments. AB50-ASA2-AA8,1011Section 10. 49.155 (6) (e) 2., 3. and 5. of the statutes are repealed. AB50-ASA2-AA8,1112Section 11. 49.175 (1) (qm) of the statutes is amended to read: AB50-ASA2-AA8,11,161349.175 (1) (qm) Quality care for quality kids. For the child care quality 14improvement activities specified in ss. 49.133, 49.155 (1g), and 49.257, $16,683,700 15$49,446,300 in each fiscal year 2022-23. In fiscal year 2023-24, for such activities, 16$28,518,700. In fiscal year 2024-25, for such activities, $46,018,700. AB50-ASA2-AA8,12,318(1) Child care quality improvement program. Using the procedure under 19s. 227.24, the department of children and families may promulgate the rules 20authorized under s. 49.133 (2) as emergency rules. Notwithstanding s. 227.24 (1) 21(c) and (2), emergency rules promulgated under this subsection remain in effect 22until July 1, 2027, or the date on which permanent rules take effect, whichever is 23sooner. Notwithstanding s. 227.24 (1) (a), (2) (b), and (3), the department of 24children and families is not required to provide evidence that promulgating a rule
1under this subsection as an emergency rule is necessary for the preservation of the 2public peace, health, safety, or welfare and is not required to provide a finding of 3emergency for a rule promulgated under this paragraph.”. AB50-ASA2-AA8,12,116601.41 (14) Value-based diabetes medication pilot project. The 7commissioner shall develop a pilot project to direct a pharmacy benefit manager, as 8defined in s. 632.865 (1) (c), and a pharmaceutical manufacturer to create a value-9based, sole-source arrangement to reduce the costs of prescription medication used 10to treat diabetes. The commissioner may promulgate rules to implement this 11subsection.”. AB50-ASA2-AA8,12,1414632.868 Insulin safety net programs. (1) Definitions. In this section: AB50-ASA2-AA8,12,1615(a) “Manufacturer” means a person engaged in the manufacturing of insulin 16that is self-administered on an outpatient basis. AB50-ASA2-AA8,12,1717(b) “Navigator” has the meaning given in s. 628.90 (3). AB50-ASA2-AA8,12,1918(c) “Patient assistance program” means a program established by a 19manufacturer under sub. (3) (a). AB50-ASA2-AA8,12,2020(d) “Pharmacy” means an entity licensed under s. 450.06 or 450.065. AB50-ASA2-AA8,12,2321(e) “Urgent need of insulin” means having less than a 7-day supply of insulin 22readily available for use and needing insulin in order to avoid the likelihood of 23suffering a significant health consequence. AB50-ASA2-AA8,13,2
1(f) “Urgent need safety net program” means a program established by a 2manufacturer under sub. (2) (a). AB50-ASA2-AA8,13,63(2) Urgent need safety net program. (a) Establishment of program. No 4later than July 1, 2026, each manufacturer shall establish an urgent need safety net 5program to make insulin available in accordance with this subsection to individuals 6who meet the eligibility requirements under par. (b). AB50-ASA2-AA8,13,87(b) Eligible individual. An individual is eligible to receive insulin under an 8urgent need safety net program if all of the following conditions are met: AB50-ASA2-AA8,13,991. The individual is in urgent need of insulin. AB50-ASA2-AA8,13,10102. The individual is a resident of this state. AB50-ASA2-AA8,13,11113. The individual is not receiving public assistance under ch. 49. AB50-ASA2-AA8,13,16124. The individual is not enrolled in prescription drug coverage through an 13individual or group health plan that limits the total cost sharing amount, including 14copayments, deductibles, and coinsurance, that an enrollee is required to pay for a 1530-day supply of insulin to no more than $75, regardless of the type or amount of 16insulin prescribed. AB50-ASA2-AA8,13,18175. The individual has not received insulin under an urgent need safety net 18program within the previous 12 months, except as allowed under par. (d). AB50-ASA2-AA8,13,2219(c) Provision of insulin under an urgent need safety net program. 1. In order 20to receive insulin under an urgent need safety net program, an individual who 21meets the eligibility requirements under par. (b) shall provide a pharmacy with all 22of the following: AB50-ASA2-AA8,14,323a. A completed application, on a form prescribed by the commissioner that
1includes an attestation by the individual, or the individual’s parent or legal 2guardian if the individual is under the age of 18, that the individual meets all of the 3eligibility requirements under par. (b). AB50-ASA2-AA8,14,44b. A valid insulin prescription. AB50-ASA2-AA8,14,75c. A valid Wisconsin driver’s license or state identification card. If the 6individual is under the age of 18, the individual’s parent or legal guardian shall 7meet this requirement. AB50-ASA2-AA8,14,1582. Upon receipt of the information described in subd. 1. a. to c., the pharmacist 9shall dispense a 30-day supply of the prescribed insulin to the individual. The 10pharmacy shall also provide the individual with the information sheet described in 11sub. (8) (b) 2. and the list of navigators described in sub. (8) (c). The pharmacy may 12collect a copayment, not to exceed $35, from the individual to cover the pharmacy’s 13costs of processing and dispensing the insulin. The pharmacy shall notify the 14health care practitioner who issued the prescription no later than 72 hours after the 15insulin is dispensed. AB50-ASA2-AA8,14,23163. A pharmacy that dispenses insulin under subd. 2. may submit to the 17manufacturer, or the manufacturer’s vendor, a claim for payment that is in 18accordance with the national council for prescription drug programs’ standards for 19electronic claims processing, except that no claim may be submitted if the 20manufacturer agrees to send the pharmacy a replacement of the same insulin in 21the amount dispensed. If the pharmacy submits an electronic claim, the 22manufacturer or vendor shall reimburse the pharmacy in an amount that covers 23the pharmacy’s acquisition cost. AB50-ASA2-AA8,15,2
14. A pharmacy that dispenses insulin under subd. 2. shall retain a copy of the 2application form described in subd. 1. a. AB50-ASA2-AA8,15,93(d) Eligibility of certain individuals. An individual who has applied for public 4assistance under ch. 49 but for whom a determination of eligibility has not been 5made or whose coverage has not become effective or an individual who has an 6appeal pending under sub. (3) (c) 4. may access insulin under this subsection if the 7individual is in urgent need of insulin. To access a 30-day supply of insulin, the 8individual shall attest to the pharmacy that the individual is described in this 9paragraph and comply with par. (c) 1. AB50-ASA2-AA8,15,1410(3) Patient assistance program. (a) Establishment of program. No later 11than July 1, 2026, each manufacturer shall establish a patient assistance program 12to make insulin available in accordance with this subsection to individuals who 13meet the eligibility requirements under par. (b). Under the patient assistance 14program, the manufacturer shall do all of the following: AB50-ASA2-AA8,15,17151. Provide the commissioner with information regarding the patient 16assistance program, including contact information for individuals to call for 17assistance in accessing the patient assistance program. AB50-ASA2-AA8,15,19182. Provide a hotline for individuals to call or access between 8 a.m. and 10 p.m. 19on weekdays and between 10 a.m. and 6 p.m. on Saturdays. AB50-ASA2-AA8,15,21203. List the eligibility requirements under par. (b) on the manufacturer’s 21website. AB50-ASA2-AA8,16,2224. Maintain the privacy of all information received from an individual 23applying for or participating in the patient assistance program and not sell, share,
1or disseminate the information unless required under this section or authorized, in 2writing, by the individual. AB50-ASA2-AA8,16,43(b) Eligible individual. An individual shall be eligible to receive insulin under 4a patient assistance program if all of the following conditions are met: AB50-ASA2-AA8,16,551. The individual is a resident of this state. AB50-ASA2-AA8,16,862. The individual, or the individual’s parent or legal guardian if the individual 7is under the age of 18, has a valid Wisconsin driver’s license or state identification 8card. AB50-ASA2-AA8,16,993. The individual has a valid insulin prescription. AB50-ASA2-AA8,16,12104. The family income of the individual does not exceed 400 percent of the 11poverty line as defined and revised annually under 42 USC 9902 (2) for a family the 12size of the individual’s family. AB50-ASA2-AA8,16,13135. The individual is not receiving public assistance under ch. 49. AB50-ASA2-AA8,16,19146. The individual is not eligible to receive health care through a federally 15funded program or receive prescription drug benefits through the U.S. department 16of veterans affairs, except that this subdivision does not apply to an individual who 17is enrolled in a policy under Part D of Medicare under 42 USC 1395w-101 et seq. if 18the individual has spent at least $1,000 on prescription drugs in the current 19calendar year. AB50-ASA2-AA8,17,2207. The individual is not enrolled in prescription drug coverage through an 21individual or group health plan that limits the total cost sharing amount, including 22copayments, deductibles, and coinsurance, that an enrollee is required to pay for a
130-day supply of insulin to no more than $75, regardless of the type or amount of 2insulin needed. AB50-ASA2-AA8,17,123(c) Application for patient assistance program. 1. An individual may apply to 4participate in a patient assistance program by filing an application with the 5manufacturer that established the patient assistance program, the individual’s 6health care practitioner if the practitioner participates in the patient assistance 7program, or a navigator included on the list under sub. (8) (c). A health care 8practitioner or navigator shall immediately submit the application to the 9manufacturer. Upon receipt of an application, the manufacturer shall determine 10the individual’s eligibility under par. (b) and, except as provided in subd. 2., notify 11the individual of the determination no later than 10 days after receipt of the 12application. AB50-ASA2-AA8,17,18132. If necessary to determine the individual’s eligibility under par. (b), the 14manufacturer may request additional information from an individual who has filed 15an application under subd. 1. no later than 5 days after receipt of the application. 16Upon receipt of the additional information, the manufacturer shall determine the 17individual’s eligibility under par. (b) and notify the individual of the determination 18no later than 3 days after receipt of the requested information. AB50-ASA2-AA8,18,2193. Except as provided in subd. 5., if the manufacturer determines under subd. 201. or 2. that the individual is eligible for the patient assistance program, the 21manufacturer shall provide the individual with a statement of eligibility. The 22statement of eligibility shall be valid for 12 months and may be renewed upon a
1determination by the manufacturer that the individual continues to meet the 2eligibility requirements under par. (b). AB50-ASA2-AA8,18,1334. If the manufacturer determines under subd. 1. or 2. that the individual is 4not eligible for the patient assistance program, the manufacturer shall provide the 5reason for the determination in the notification under subd. 1. or 2. The individual 6may appeal the determination by filing an appeal with the commissioner that shall 7include all of the information provided to the manufacturer under subds. 1. and 2. 8The commissioner shall establish procedures for deciding appeals under this 9subdivision. The commissioner shall issue a decision no later than 10 days after the 10appeal is filed, and the commissioner’s decision shall be final. If the commissioner 11determines that the individual meets the eligibility requirements under par. (b), the 12manufacturer shall provide the individual with the statement of eligibility 13described in subd. 3. AB50-ASA2-AA8,18,22145. In the case of an individual who has prescription drug coverage through an 15individual or group health plan, if the manufacturer determines under subd. 1. or 2. 16that the individual is eligible for the patient assistance program but also 17determines that the individual’s insulin needs are better addressed through the use 18of the manufacturer’s copayment assistance program rather than the patient 19assistance program, the manufacturer shall inform the individual of the 20determination and provide the individual with the necessary coupons to submit to 21a pharmacy. The individual may not be required to pay more than the copayment 22amount specified in par. (d) 2. AB50-ASA2-AA8,19,623(d) Provision of insulin under a patient assistance program. 1. Upon receipt
1from an individual of the eligibility statement described in par. (c) 3. and a valid 2insulin prescription, a pharmacy shall submit an order containing the name of the 3insulin and daily dosage amount to the manufacturer. The pharmacy shall include 4with the order the pharmacy’s name, shipping address, office telephone number, 5fax number, email address, and contact name, as well as any days or times when 6deliveries are not accepted by the pharmacy. AB50-ASA2-AA8,19,1572. Upon receipt of an order meeting the requirements under subd. 1., the 8manufacturer shall send the pharmacy a 90-day supply of insulin, or lesser amount 9if requested in the order, at no charge to the individual or pharmacy. The pharmacy 10shall dispense the insulin to the individual associated with the order. The insulin 11shall be dispensed at no charge to the individual, except that the pharmacy may 12collect a copayment from the individual to cover the pharmacy’s costs for processing 13and dispensing in an amount not to exceed $50 for each 90-day supply of insulin. 14The pharmacy may not seek reimbursement from the manufacturer or a 3rd-party 15payer. AB50-ASA2-AA8,19,18163. The pharmacy may submit a reorder to the manufacturer if the individual’s 17eligibility statement described in par. (c) 3. has not expired. The reorder shall be 18treated as an order for purposes of subd. 2. AB50-ASA2-AA8,19,21194. Notwithstanding subds. 2. and 3., a manufacturer may send the insulin 20directly to the individual if the manufacturer provides a mail-order service option, 21in which case the pharmacy may not collect a copayment from the individual. AB50-ASA2-AA8,20,222(4) Exceptions. (a) This section does not apply to a manufacturer that shows
1to the commissioner’s satisfaction that the manufacturer’s annual gross revenue 2from insulin sales in this state does not exceed $2,000,000.
/2025/related/amendments/ab50/aa8_asa2_ab50
true
amends
/2025/related/amendments/ab50/aa8_asa2_ab50/7/_1
amends/2025/REG/AB50-ASA2-AA8,10,19
amends/2025/REG/AB50-ASA2-AA8,10,19
section
true